GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
Ted W. Love, M.D.Location
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more effective a company is in implementing good security practices.
Learn more about the latest issues in cybersecurity
A data breach is a security incident where sensitive, protected confidential information is copied, ...
Cybersecurity risk is the probability of a cyber attack or data breach on your organization. ...
Compare Global Blood Therapeutics's security performance with other companies